Navigation Links
Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Date:3/11/2009

CRANBURY, N.J., March 11 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company's President and Chief Executive Officer John F. Crowley will be presenting at the upcoming Cowen and Company 29th Annual Healthcare Conference. Mr. Crowley's presentation is scheduled to begin on Tuesday, March 17 at 9:30 a.m. Eastern Time.

Individuals can listen to a live webcast of the presentation by logging on to the Investors section of the Amicus Therapeutics' Web site, http://www.amicustherapeutics.com. Participants should allow approximately five to ten minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. A replay of the webcast will also be available on the Company's Web site for 30 days.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs.

FOLD -G


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amicus Therapeutics Announces Change to Board of Directors
2. Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
3. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
4. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
5. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
6. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
7. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
8. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
9. Amicus Therapeutics Opens Research Facility in San Diego
10. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
11. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014 Regulus ... biopharmaceutical company leading the discovery and development of innovative ... financial results and highlights for the quarter ended June ... U.S. financial markets close. Regulus will ... 6, 2014, at 5:00 pm Eastern Daylight Time to ...
(Date:7/30/2014)... and PARIS , July 30, ... (EURONEXT: SAN and NYSE: SNY) today announced that the ... Administration (FDA) rare pediatric disease priority review voucher in ... alirocumab.  The priority review voucher entitles the holder to ... an expedited 6-month review from the filing date instead ...
(Date:7/30/2014)... W. R. Grace & Co. (NYSE: ... REVELERIS® Prep purification system , a dual-mode instrument ... researchers to perform both flash and preparative liquid ... the REVELERIS® Prep purification system, researchers can easily ... a simple touch of the screen, giving them ...
(Date:7/30/2014)... BURLINGTON, Mass. , July 30, 2014 /PRNewswire/ ... surveyed pharmacy and medical directors in ... key drivers of biosimilar market penetration will be ... care organizations (MCOs) and the expected lower cost ... strategies for biosimilars that meet their pricing expectations ...
Breaking Biology Technology:Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Grace Launches New REVELERIS® Prep Purification System 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3
... TORONTO, May 5 /PRNewswire-FirstCall/ - Lorus Therapeutics ... company dedicated in,the research, development and commercialization ... of cancer, announced today that it has,strengthened ... of Dr. Saeid,Babaei to Vice-President of Business ...
... 8, 2008, at,8:30 a.m. Eastern/2:30 p.m. Central European/5:30 ... CTIC ; MTA) management team will,host a ... first,quarter achievements and financial results., Conference ... a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time ...
... - YM BioSciences Inc.,(AMEX: YMI , TSX: ... and commercializes differentiated products for patients worldwide,today announced ... product AeroLEF(TM) will be presented at The 27th ... takes place May,8-10, 2008 in Tampa, Florida., ...
Cached Biology Technology:Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions 2Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions 3Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions 4YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR AEROLEF(TM) AT AMERICAN PAIN SOCIETY ANNUAL MEETING 2
(Date:7/30/2014)... University is paving the way for a breakthrough ... military troops exposed to poisonous chemicalsparticularly those in ... in the current issue of the journal ... which are compounds commonly used in pesticides and ... NYU School of Engineering Associate Professor of Chemical ...
(Date:7/30/2014)... reversible epigenetic processes to regulate its genes, and adapt ... picture of the genome regulation taking place in the ... Genome Biology and illustrates how the truffle deals ... The authors say this may shed light on how ... truffles (Tuber melanosporum), also known as Prigord truffles, have ...
(Date:7/30/2014)... the Red Queen in Lewis Carroll,s Through the ... and National University of Singapore improved a 35-year-old ... over decades to millions of years. , The ... competition, incorporates the "Red Queen Effect," an evolutionary ... 1970s, which suggests that organisms must constantly increase ...
Breaking Biology News(10 mins):Engineering a protein to prevent brain damage from toxic agents 2How black truffles deal with the jumpers in their genome 2Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3
... telescopes to restore vision, and smart nappies to detect ... technologies that promise to transform medicine, according to this ... are made by Professor Donald Combs of the Eastern ... that are in varying stages of development and on ...
... Despite the fact that the people of India ... population, they have been underrepresented in studies related ... modernization, complex genetic diseases associated with urban and ... genetic cataloging and association studies of particular importance. ...
... first-ever computed tomography (CT) evaluation of King Tutankhamun’s mummy ... ancient pharaoh died. The CT images and results of ... of the Radiological Society of North America (RSNA). , ... Cairo University in Egypt, was part of an international ...
Cached Biology News:Five new technologies that promise to transform medicine 2Researchers make progress in studying genetic traits of India-born populations 2Radiologists attempt to solve mystery of Tut's demise 2
anti-JNK2 Immunogen: Recombinant human JNK2 protein Accession Number: NM_002752 Quality Assurance: Routinely evaluated by immunoblot. Molecular Weight: 46 and/or 54 kDa Available ...
... Clone/PAD: ZMD.330. Immunogen: Synthetic peptide derived ... rat and mouse protein kinase C zeta ... rat and mouse PKCzeta protein. Recognizes ... not cross-react with PKCiota/lambda. Reactivity: Mouse ...
Lipid-rich bovine serum albumin for cell culture. It is chromatographically purified and has an IgG content 1.0% (w/w)....
Request Info...
Biology Products: